Logo image of ALLO

ALLOGENE THERAPEUTICS INC (ALLO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ALLO - US0197701065 - Common Stock

1.42 USD
0 (0%)
Last: 12/19/2025, 8:27:52 PM
1.44 USD
+0.02 (+1.41%)
After Hours: 12/19/2025, 8:27:52 PM
Fundamental Rating

3

ALLO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. ALLO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, ALLO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALLO had negative earnings in the past year.
In the past year ALLO has reported a negative cash flow from operations.
ALLO had negative earnings in each of the past 5 years.
In the past 5 years ALLO always reported negative operating cash flow.
ALLO Yearly Net Income VS EBIT VS OCF VS FCFALLO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

ALLO's Return On Assets of -48.21% is in line compared to the rest of the industry. ALLO outperforms 51.88% of its industry peers.
ALLO has a Return On Equity (-67.24%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -48.21%
ROE -67.24%
ROIC N/A
ROA(3y)-46.19%
ROA(5y)-36.74%
ROE(3y)-58.29%
ROE(5y)-45.22%
ROIC(3y)N/A
ROIC(5y)N/A
ALLO Yearly ROA, ROE, ROICALLO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALLO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALLO Yearly Profit, Operating, Gross MarginsALLO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200K -400K -600K -800K -1M

More info and screens

6

2. Health

2.1 Basic Checks

ALLO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALLO has been increased compared to 1 year ago.
The number of shares outstanding for ALLO has been increased compared to 5 years ago.
ALLO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALLO Yearly Shares OutstandingALLO Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
ALLO Yearly Total Debt VS Total AssetsALLO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -5.80, we must say that ALLO is in the distress zone and has some risk of bankruptcy.
ALLO has a Altman-Z score of -5.80. This is in the lower half of the industry: ALLO underperforms 64.10% of its industry peers.
ALLO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.8
ROIC/WACCN/A
WACC8.8%
ALLO Yearly LT Debt VS Equity VS FCFALLO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 8.19 indicates that ALLO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 8.19, ALLO is in the better half of the industry, outperforming 74.81% of the companies in the same industry.
ALLO has a Quick Ratio of 8.19. This indicates that ALLO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 8.19, ALLO is in the better half of the industry, outperforming 74.81% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.19
Quick Ratio 8.19
ALLO Yearly Current Assets VS Current LiabilitesALLO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.78% over the past year.
Looking at the last year, ALLO shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
ALLO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -91.70% yearly.
EPS 1Y (TTM)33.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.63%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-91.7%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 17.92% on average over the next years. This is quite good.
ALLO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 475.53% yearly.
EPS Next Y30.07%
EPS Next 2Y15.25%
EPS Next 3Y10.53%
EPS Next 5Y17.92%
Revenue Next Year-79.12%
Revenue Next 2Y-35.39%
Revenue Next 3Y749.42%
Revenue Next 5Y475.53%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALLO Yearly Revenue VS EstimatesALLO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ALLO Yearly EPS VS EstimatesALLO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALLO. In the last year negative earnings were reported.
Also next year ALLO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALLO Price Earnings VS Forward Price EarningsALLO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALLO Per share dataALLO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.25%
EPS Next 3Y10.53%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALLO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ALLOGENE THERAPEUTICS INC

NASDAQ:ALLO (12/19/2025, 8:27:52 PM)

After market: 1.44 +0.02 (+1.41%)

1.42

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-11 2026-03-11/amc
Inst Owners50.13%
Inst Owner Change-9.79%
Ins Owners6.83%
Ins Owner Change-0.06%
Market Cap319.12M
Revenue(TTM)N/A
Net Income(TTM)-212.01M
Analysts82
Price Target7.71 (442.96%)
Short Float %11.76%
Short Ratio7.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.05%
Min EPS beat(2)16.55%
Max EPS beat(2)17.55%
EPS beat(4)4
Avg EPS beat(4)14.25%
Min EPS beat(4)5.26%
Max EPS beat(4)17.64%
EPS beat(8)8
Avg EPS beat(8)9.76%
EPS beat(12)11
Avg EPS beat(12)9.95%
EPS beat(16)15
Avg EPS beat(16)10.24%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0.33%
EPS NQ rev (3m)1.73%
EPS NY rev (1m)7.63%
EPS NY rev (3m)7.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)25%
Revenue NY rev (3m)25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.01
P/tB 1.01
EV/EBITDA N/A
EPS(TTM)-0.98
EYN/A
EPS(NY)-0.89
Fwd EYN/A
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.7
OCFYN/A
SpS0
BVpS1.4
TBVpS1.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.21%
ROE -67.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.19%
ROA(5y)-36.74%
ROE(3y)-58.29%
ROE(5y)-45.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.13%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.19
Quick Ratio 8.19
Altman-Z -5.8
F-Score3
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)17.35%
Cap/Depr(5y)225.27%
Cap/Sales(3y)2304.28%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.63%
EPS Next Y30.07%
EPS Next 2Y15.25%
EPS Next 3Y10.53%
EPS Next 5Y17.92%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-91.7%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-79.12%
Revenue Next 2Y-35.39%
Revenue Next 3Y749.42%
Revenue Next 5Y475.53%
EBIT growth 1Y56.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.4%
EBIT Next 3Y2.25%
EBIT Next 5Y4.47%
FCF growth 1Y36.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.67%
OCF growth 3YN/A
OCF growth 5YN/A

ALLOGENE THERAPEUTICS INC / ALLO FAQ

What is the fundamental rating for ALLO stock?

ChartMill assigns a fundamental rating of 3 / 10 to ALLO.


What is the valuation status for ALLO stock?

ChartMill assigns a valuation rating of 0 / 10 to ALLOGENE THERAPEUTICS INC (ALLO). This can be considered as Overvalued.


What is the profitability of ALLO stock?

ALLOGENE THERAPEUTICS INC (ALLO) has a profitability rating of 1 / 10.


What is the financial health of ALLOGENE THERAPEUTICS INC (ALLO) stock?

The financial health rating of ALLOGENE THERAPEUTICS INC (ALLO) is 6 / 10.


What is the earnings growth outlook for ALLOGENE THERAPEUTICS INC?

The Earnings per Share (EPS) of ALLOGENE THERAPEUTICS INC (ALLO) is expected to grow by 30.07% in the next year.